Veraxa Biotech is trading at $1.09, up 7.92%, amid a biotech-sector rally; no company-specific catalyst was identified. - XBI was up during the session amid M&A activity and positive clinical-trial news. - The latest release on the company’s investor page is dated October 13; no new company-specific announcement was identified for October 21. - Earlier proof-of-concept data are prior news, not a new October 21 event.